CQ

CRISPR QC™, Inc. - Company Research Report



Company Overview



Name: CRISPR QC™, Inc.

Mission: No information is available.

Founded: No information is available.

Founders: No information is available.

Key People:
  • No information is available.


Headquarters: 8949 Kenamar Dr. Suite 101, San Diego, CA 92121, California, United States

Number of Employees: No information is available.

Revenue: No information is available.

Known For:
CRISPR QC™, Inc. is a biotechnology company known for its CRISPR Analytics Platform, which provides comprehensive measurements and analysis around CRISPR activity. This platform enables scientists and researchers to optimize gene editing outcomes and ensure the highest levels of quality control.

Products



CRISPR Analytics Platform™


High-level Description:
The CRISPR Analytics Platform™ is an advanced tool designed to provide real-time kinetic insights into CRISPR-Cas biochemistry. It integrates three key components into one comprehensive platform for optimizing CRISPR efficiency and accuracy.

Key Features:
  • Quantitative measurement of RNP formation, DNA target binding, and cleavage activity.

  • Real-time insights into RNP assembly dynamics.

  • Direct, actionable data to optimize CRISPR workflows.

  • Reduces costs, variability, and increases reproducibility.

  • Faster time to market and more confident data-driven decisions.


CRISPR-Chip™


High-level Description:
The CRISPR-Chip™ is a cutting-edge biosensor that combines the sensitivity of a graphene-based field-effect transistor with CRISPR specificity, enabling quantitative in vitro analysis of CRISPR-Cas biochemistry.

Key Features:
  • Graphene-based biosensor for enhanced sensitivity.

  • Real-time analysis of binding interactions or cleavage reactions.

  • Actionable insights for research with unparalleled accuracy and efficiency.

  • Quantitative assessment of binding interactions and cleavage reactions.


Recent Developments



Recent Developments in the Company:


Case Studies and Applications:
  • July 25, 2024: Optimizing Ribonucleoprotein (RNP) Complexes and Improving Multiplex Gene Editing Efficiency with Data-Driven gRNA Selection. This study showcases the role of CRISPR QC's insights in improving gene editing workflows.

  • July 25, 2024: Accelerating CRISPR-Cas Optimization with Quantitative DNA Binding Analysis. This case study highlights the importance of the CRISPR QC platform in genomic studies, sustainability research, and therapeutic development.

  • July 25, 2024: In vitro CRISPR-Cas Cleavage Assays Streamline Gene Editing Workflows. The platform's role in enhancing workflow efficiency for gene editing research is discussed.


New Products Launched:


Introduction of CRISPR-Chip™, a technology that integrates CRISPR specificity with graphene-based field-effect transistor sensitivity for comprehensive and real-time biochemical analysis.

New Features Added to Existing Products:


No information is available.

New Partnerships:


No information is available.

Conclusion



CRISPR QC™, Inc. continues to innovate in the field of gene editing, leveraging its proprietary technologies like the CRISPR Analytics Platform™ and CRISPR-Chip™. These developments enable significant advancements in CRISPR-Cas optimization, enhancing reproducibility, and accelerating research timelines. The company's products are positioned to provide real-time, actionable insights that are crucial for confident decision-making and optimized gene editing outcomes.